Identification of Genes Modulated by Interferon Gamma in Breast Cancer Cells

Overview

Journal Biochem Biophys Rep

Specialty Biochemistry

Date 2021 Jun 30

PMID 34189281

Citations 9

Authors

Angeles C Tecalco-Cruz

Marina Macias-Silva

Josue Orlando Ramirez-Jarquin

Bruno Mendez-Ambrosio

Affiliations

Soon will be listed here.

Abstract

Interferon gamma (IFNγ) plays a context-dependent dual tumor-suppressor and pro-tumorigenic roles in cancer. IFNγ induces morphological changes in breast cancer (BC) cells with or without estrogen receptor alpha (ERα) expression. However, IFNγ-regulated genes in BC cells remain unexplored. Here, we performed a cDNA microarray analysis of MCF-7 (ERα+) and MDA-MB-231 (HER2-/PR-/ERα-) cells with and without IFNγ treatment. We identified specific IFNγ-modulated genes in each cell type, and a small group of genes regulated by IFNγ common in both cell types. IFNγ treatment for an extended time mainly repressed gene expression shared by both cell types. Nonetheless, some of these IFNγ-repressed genes were seemingly deregulated in human mammary tumor samples, along with decreased (an IFNγ receptor) expression. Thus, IFNγ signaling-elicited anti-tumor activities may be mediated by the downregulation of main IFNγ target genes in BC; however, it may be deregulated by the tumor microenvironment in a tumor stage-dependent manner.

Citing Articles

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Serrano Garcia L, Javega B, Llombart Cussac A, Gion M, Perez-Garcia J, Cortes J Front Immunol. 2024; 15:1513421.

PMID: 39735530 PMC: 11671371. DOI: 10.3389/fimmu.2024.1513421.

Extracellular vesicles from human breast cancer-resistant cells promote acquired drug resistance and pro-inflammatory macrophage response.

Santos P, Rezende C, Piraine R, Oliveira B, Ferreira F, Carvalho V Front Immunol. 2024; 15:1468229.

PMID: 39474419 PMC: 11518763. DOI: 10.3389/fimmu.2024.1468229.

Non-canonical deubiquitination of OTUB1 induces IFNγ-mediated cell cycle arrest via regulation of p27 stability.

Lee S, Woo S, Seo S, Lee H, Kim S, Chang Y Oncogene. 2024; 43(24):1852-1860.

PMID: 38664499 PMC: 11164677. DOI: 10.1038/s41388-024-03042-z.

Regional analysis to delineate intrasample heterogeneity with RegionalST.

Lyu Y, Wu C, Sun W, Li Z Bioinformatics. 2024; 40(4).

PMID: 38579257 PMC: 11026142. DOI: 10.1093/bioinformatics/btae186.

Deregulation of interferon-gamma receptor 1 expression and its implications for lung adenocarcinoma progression.

Tecalco-Cruz A, Medina-Abreu K, Oropeza-Martinez E, Zepeda-Cervantes J, Vazquez-Macias A, Macias-Silva M World J Clin Oncol. 2024; 15(2):195-207.

PMID: 38455133 PMC: 10915940. DOI: 10.5306/wjco.v15.i2.195.

References

Barbosa A, Martel F . Targeting Glucose Transporters for Breast Cancer Therapy: The Effect of Natural and Synthetic Compounds. Cancers (Basel). 2020; 12(1). PMC: 7016663. DOI: 10.3390/cancers12010154. View

Jitariu A, Cimpean A, Ribatti D, Raica M . Triple negative breast cancer: the kiss of death. Oncotarget. 2017; 8(28):46652-46662. PMC: 5542300. DOI: 10.18632/oncotarget.16938. View

Soave C, Guerin T, Liu J, Dou Q . Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer Metastasis Rev. 2017; 36(4):717-736. PMC: 5722705. DOI: 10.1007/s10555-017-9705-x. View

Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T . Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat. 2006; 104(1):21-30. DOI: 10.1007/s10549-006-9393-7. View

Ghoroghi S, Mary B, Larnicol A, Asokan N, Klein A, Osmani N . Ral GTPases promote breast cancer metastasis by controlling biogenesis and organ targeting of exosomes. Elife. 2021; 10. PMC: 7822591. DOI: 10.7554/eLife.61539. View

Alspach E, Lussier D, Schreiber R . Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harb Perspect Biol. 2018; 11(3). PMC: 6396335. DOI: 10.1101/cshperspect.a028480. View

Tarhan Y, Kato T, Jang M, Haga Y, Ueda K, Nakamura Y . Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. Neoplasia. 2016; 18(5):265-272. PMC: 4887616. DOI: 10.1016/j.neo.2016.03.005. View

Szklarczyk D, Morris J, Cook H, Kuhn M, Wyder S, Simonovic M . The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2016; 45(D1):D362-D368. PMC: 5210637. DOI: 10.1093/nar/gkw937. View

Brandhagen B, Tieszen C, Ulmer T, Tracy M, Goyeneche A, Telleria C . Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics. BMC Cancer. 2013; 13:35. PMC: 3562154. DOI: 10.1186/1471-2407-13-35. View

10.

Desai S, Haas A, Wood L, Tsai Y, Pestka S, Rubin E . Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res. 2006; 66(2):921-8. DOI: 10.1158/0008-5472.CAN-05-1123. View

11.

Tecalco-Cruz A, Ramirez-Jarquin J, Cruz-Ramos E . Estrogen Receptor Alpha and its Ubiquitination in Breast Cancer Cells. Curr Drug Targets. 2018; 20(6):690-704. DOI: 10.2174/1389450119666181015114041. View

12.

Zaidi M . The Interferon-Gamma Paradox in Cancer. J Interferon Cytokine Res. 2018; 39(1):30-38. PMC: 6350411. DOI: 10.1089/jir.2018.0087. View

13.

West K, Kelliher J, Xu Z, An L, Reed M, Eoff R . LC8/DYNLL1 is a 53BP1 effector and regulates checkpoint activation. Nucleic Acids Res. 2019; 47(12):6236-6249. PMC: 6614850. DOI: 10.1093/nar/gkz263. View

14.

Legrier M, Bieche I, Gaston J, Beurdeley A, Yvonnet V, Deas O . Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. Br J Cancer. 2015; 114(2):177-87. PMC: 4815803. DOI: 10.1038/bjc.2015.398. View

15.

Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H . Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2012; 41(Database issue):D1040-6. PMC: 3531205. DOI: 10.1093/nar/gks1215. View

16.

Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry J . Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-9. PMC: 3037419. DOI: 10.1038/75556. View

17.

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T . Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676-82. PMC: 3855844. DOI: 10.1038/nmeth.2019. View

18.

Yang S, Yu M, Sun L, Xiao W, Yang X, Sun L . Interferon-γ-induced intestinal epithelial barrier dysfunction by NF-κB/HIF-1α pathway. J Interferon Cytokine Res. 2013; 34(3):195-203. DOI: 10.1089/jir.2013.0044. View

19.

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

20.

Gooch J, HERRERA R, Yee D . The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth Differ. 2000; 11(6):335-42. View